PER-086-02已完成1 期
STUDY PHASE III, MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, CLINICAL USE AGAINST PLACEBO, TO EVALUATE THE SAFETY AND TOLERANCE OF BMS-188667 INTRAVENOUSLY ADMINISTERED IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (AR), WITH OR WITHOUT CONCOMITANT DISEASES, AND WHO RECEIVE ANTIRREUMATIC DRUGS (DMARDS) THAT MODIFY THE NATURAL HISTORY OF THE DISEASE AND / OR BIOLOGICAL PRODUCTS APPROVED FOR AR.
BRISTOL MYERS SQUIBB PERU S.A.,0 个研究点目标入组 0 人开始时间: 2002年12月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid arthritis and the American College of Rheumatology functional classes I, II III or IV
- •Participants must be taking 1 or more DMARDs and/or biologic approved for rheumatoid arthritis (RA) for at least 3 months and be on a stable dose for 28 days prior to Day 1.
排除标准
- •Other auto-immune disease as a main diagnosis (e.g. Systemic Lupus Erythematosus [SLE], Scleroderma)
- •Active tuberculosis (TB) requiring treatment within last 3 years
研究者
相似试验
已完成
1 期
STUDY PHASE III, RANDOMIZED, MULTICENTRIC, DOUBLE-BLIND, CONTROLLED BY PLACEBO TO EVALUATE THE SAFETY AND EFFICACY OF BMS 298585, IN COMBINATION WITH GLIBENCLAMIDE IN PATIENTS WITH DIABETES MELLITUS TYPE 2 THAT HAVE INAPPROPRIATE GLYCEMIC CONTROL WITH SULFONILUREA AS MONOTHERAPY.-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-038-03BRISTOL MYERS SQUIBB PERU S.A.,
已完成
1 期
MULTICENTRIC STUDY, IN PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED WITH PLACEBO, TO EVALUATE THE SAFETY AND EFFICACY OF BMS-298585 IN COMBINATION WITH METFORMIN, FOR THE TREATMENT OF INDIVIDUALS WITH DIABETES TYPE 2 THAT PRESENT AN INAPPROPRIATE CONTROL WITH METFORMIN AS MONOTHERAPY.PER-041-03BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
1 期
Estudio fase III, multicéntrico, randomizado, doble ciego, controlado con placebo, de eficacia y seguridad de Apremilast (CC-10004) en pacientes con psoriasis en placas moderada o severa. A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasisPsoriasis, una enfermedad crónica inflamatoria de la piel, se calcula que afecta hasta el 2,5% de la población mundial. La psoriasis en placas es la forma más común de esta enfermedad.?Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world'spopulation. Plaque-type psoriasis is the most common form of this disease.MedDRA version: 12.1Level: LLTClassification code 10037153Term: PsoriasisEUCTR2010-019992-30-ESCelgene Corporation405
进行中（未招募）
不适用
Estudio fase III, multicéntrico, randomizado, abierto, para comparar la eficacia y seguridad de un régimen de tratamiento basado en Sitagliptina frente a un régimen de tratamiento basado en Liraglutida en pacientes con Diabetes Mellitus Tipo 2 en monoterapia con Metformina que no han alcanzado un adecuado control glucémico.A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy.Diabetes Mellitus tipo 2Type 2 diabetes mellitusMedDRA version: 13Level: PTClassification code 10067585Term: Diabetes mellitus tipo 2EUCTR2010-023759-27-ESMerck Sharp & Dohme Corp600
进行中（未招募）
不适用
Estudio fase III, multicéntrico, randomizado, controlado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y eficacia de Rituximab en combinación con metotrexato (MTX), en comparación con metotrexato sólo en pacientes con artritis reumatoide activa no tratados previamente con metotrexato”EUCTR2005-002395-15-ESF. Hoffmann-La Roche Ltd.853